Results announcement for the third quarter 2013

Wednesday 23 October

GSK announces Q3 core EPS growth of16% and dividend of 19p

Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
Pharma Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%,
Consumer Healthcare +4%
Fourapprovals in three markets; Tivicay for HIV and FluLaval Q-IV vaccine for flu; Tafinlar for metastatic melanoma; Relvar Ellipta for asthma
Q3 dividend of 19p (+6%)
Full year 2013 guidance reaffirmed

View full Q3 2013 results (PDF)

More informationincludingincluding CFO interview are available in thequarterly resultssection of this website.

You just read:

Results announcement for the third quarter 2013

Distribution channels: Companies

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.